DK0582368T3 - Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet - Google Patents

Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet

Info

Publication number
DK0582368T3
DK0582368T3 DK93304102T DK93304102T DK0582368T3 DK 0582368 T3 DK0582368 T3 DK 0582368T3 DK 93304102 T DK93304102 T DK 93304102T DK 93304102 T DK93304102 T DK 93304102T DK 0582368 T3 DK0582368 T3 DK 0582368T3
Authority
DK
Denmark
Prior art keywords
treatment
nervous system
central nervous
system disorders
alkyl
Prior art date
Application number
DK93304102T
Other languages
Danish (da)
English (en)
Inventor
David Edward Tupper
John Fairhurst
Terrence Michael Hotten
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0582368T3 publication Critical patent/DK0582368T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK93304102T 1992-05-29 1993-05-26 Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet DK0582368T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
DK0582368T3 true DK0582368T3 (da) 2001-02-05

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93304102T DK0582368T3 (da) 1992-05-29 1993-05-26 Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet

Country Status (21)

Country Link
EP (1) EP0582368B1 (enExample)
JP (1) JP3219541B2 (enExample)
CN (1) CN1043994C (enExample)
AT (1) ATE198891T1 (enExample)
AU (1) AU668159B2 (enExample)
CA (1) CA2097016A1 (enExample)
CZ (1) CZ282783B6 (enExample)
DE (1) DE69329887T2 (enExample)
DK (1) DK0582368T3 (enExample)
ES (1) ES2153373T3 (enExample)
FI (1) FI101538B1 (enExample)
GR (1) GR3035587T3 (enExample)
HU (1) HU218278B (enExample)
IL (1) IL105827A (enExample)
MX (1) MX9303124A (enExample)
MY (1) MY109943A (enExample)
NO (1) NO305125B1 (enExample)
NZ (1) NZ247703A (enExample)
PT (1) PT582368E (enExample)
RU (1) RU2125574C1 (enExample)
TW (1) TW268005B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
CZ298198A3 (cs) * 1996-03-25 1999-06-16 Eli Lilly And Company Farmaceutický přípravek
EP0932407A4 (en) * 1996-03-25 2002-04-24 Lilly Co Eli TECHNIQUE FOR TREATING MIGRAINE PAIN
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
HU226167B1 (hu) 1996-09-23 2008-05-28 Lilly Co Eli Olanzapin-dihidrát D, elõállítása és az azt tartalmazó gyógyszerkészítmények
WO1998013027A1 (en) * 1996-09-24 1998-04-02 Eli Lilly And Company Coated particle formulation
RU2185383C1 (ru) * 2001-05-22 2002-07-20 Институт молекулярной генетики РАН ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
US9303041B2 (en) * 2012-08-21 2016-04-05 Janssen Pharmaceutica Nv Haptens of olanzapine
ES2788716T3 (es) 2012-08-21 2020-10-22 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
ES2870004T3 (es) 2012-08-21 2021-10-26 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
HK1211958A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
EP2888284B1 (en) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Antibodies to risperidone haptens and use thereof
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
AU2013305936B2 (en) 2012-08-21 2017-08-03 Saladax Biomedical Inc. Haptens of risperidone and paliperidone
PL2888258T3 (pl) 2012-08-21 2019-10-31 Janssen Pharmaceutica Nv Hapteny paliperydonu
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
ES2762105T3 (es) 2012-08-21 2020-05-22 Janssen Pharmaceutica Nv Anticuerpos para aripiprazol y uso de los mismos
PT3305784T (pt) 2012-08-21 2020-10-23 Janssen Pharmaceutica Nv Haptenos de quetiapina para utilização em ensaios imunológicos
EP2888285B1 (en) 2012-08-21 2024-04-17 Janssen Pharmaceutica NV Antibodies to aripiprazole haptens and use thereof
TR201910347T4 (tr) 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
CA2882615C (en) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine and use thereof
CN107253993B (zh) 2012-08-21 2021-10-22 詹森药业有限公司 奥氮平的抗体及其用途
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
JP6994461B2 (ja) 2015-12-17 2022-02-04 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンに対する抗体及びその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569730A5 (enExample) * 1972-04-04 1975-11-28 Wander Ag Dr A
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
US4061752A (en) * 1975-08-06 1977-12-06 Sandoz Ltd. 6-Piperazino-11-methylene-dibenzazepines[b,e]
FI762646A7 (enExample) * 1975-09-24 1977-03-25 Sandoz Ag
CH624682A5 (enExample) * 1976-11-10 1981-08-14 Sandoz Ag
US4761411A (en) * 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
EP0582368B1 (en) 2001-01-24
FI101538B (fi) 1998-07-15
JP3219541B2 (ja) 2001-10-15
CZ282783B6 (cs) 1997-10-15
JPH0687862A (ja) 1994-03-29
HUT66180A (en) 1994-09-28
IL105827A0 (en) 1993-09-22
CA2097016A1 (en) 1993-11-30
FI101538B1 (fi) 1998-07-15
NO931917L (no) 1993-11-30
AU3980793A (en) 1993-12-02
EP0582368A1 (en) 1994-02-09
MX9303124A (es) 1993-11-01
AU668159B2 (en) 1996-04-26
FI932445A0 (fi) 1993-05-28
ATE198891T1 (de) 2001-02-15
HU9301579D0 (en) 1993-09-28
GR3035587T3 (en) 2001-06-29
IL105827A (en) 1997-02-18
NO931917D0 (no) 1993-05-26
CN1043994C (zh) 1999-07-07
CZ102493A3 (en) 1993-12-15
MY109943A (en) 1997-10-31
ES2153373T3 (es) 2001-03-01
CN1085903A (zh) 1994-04-27
DE69329887T2 (de) 2001-05-23
FI932445L (fi) 1993-11-30
TW268005B (enExample) 1996-01-11
NO305125B1 (no) 1999-04-06
NZ247703A (en) 1995-07-26
RU2125574C1 (ru) 1999-01-27
HU218278B (en) 2000-07-28
PT582368E (pt) 2001-05-31
DE69329887D1 (de) 2001-03-01

Similar Documents

Publication Publication Date Title
DK0582368T3 (da) Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
FR2662162B1 (fr) Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
ES2054020T3 (es) Compuestos biologicamente activos.
NO821494L (no) Terapeutisk nyttige 1-alkyl-2-aminotetralinderivater
NO893205D0 (no) Kjemiske forbindelser.
MX9202803A (es) Nuevos compuestos de benzopirano y procedimiento para su preparacion.
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
DK0594099T3 (da) Fremgangsmåde til rensning af rå clavulansyre
ATE264104T1 (de) Immunmodulierende arzneimittelzusammenstellung
ATE98230T1 (de) Indolderivate.
DE69327077D1 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen
DE69527854D1 (de) Derivate substituierter amidinonaphthylester
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
DE3867494D1 (de) Fluor enthaltende vitamin-d2-derivate.
DK0501442T3 (da) 8-Chlor-benzothiazepin-forbindelse til forebyggelse og behandling af følgerne af cerebral nekrose af nerveceller
ES2133095A1 (es) Acidos alquilidenglutaminicos con propiedades farmaceuticas.